Thrombomodulin as a marker of endothelium damage in some clinical conditions

Remková, Anna; Kováčová, Eva; Príkazská, M; Kratochvílová, Helena

doi:10.1016/s0953-6205(00)00066-2

Cited by 30 publications

(22 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some findings in hypertension suggest that TM is released into the plasma only by true endothelial cell damage during development of vascular complications. 10,14,[18][19][20] . Probably a certain degree of endothelial injury is necessary for its plasma increase.…”

Section: Discussionmentioning

confidence: 99%

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Remková

Kratochvílová

2002

J Hum Hypertens

View full text Add to dashboard Cite

The aim of the study was to investigate the effect of therapy by rilmenidine on endothelial and platelet function in 23 patients with the early stages of untreated essential hypertension. The measurements were carried out before therapy, after 1 week of placebo administration, after 1 week, after 1 month and after 3 months of therapy. After 1 week of therapy both systolic (SBP) and diastolic blood pressure (DBP) were reduced (P Ͻ 0.001) all over the study period. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, and plasma ␤-thromboglobulin (␤TG) as an indicator of in vivo platelet activation, were investigated. Fibrinogen as a risk factor for vascular changes was also assayed. Platelet aggregation without stimulation (spontaneous, SPA) and induced by adre-

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Remková

Kratochvílová

2002

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…This raises the question of whether soluble TM is elevated in patients with hypertension in proportion to the progression of atherosclerosis. However, few studies have reported the blood concentration of soluble TM in hypertension (17)(18)(19). Thus, the present study was designed to determine the clinical significance of the circulating soluble TM level in patients with hypertension.…”

Section: Introductionmentioning

confidence: 99%

Circulating Thrombomodulin Levels Are Related to Latent Progression of Atherosclerosis in Hypertensive Patients.

et al. 2003

View full text Add to dashboard Cite

show abstract

“…In some pathological states, the soluble thrombomodulin concentration may reflect the degree of vascular damage and associated inflammation rather than the expression level of thrombomodulin. Indeed, in hypertensive patients, thrombomodulin levels were higher [12] or tended to be higher [9] than in normotensive patients.…”

Section: Discussionmentioning

confidence: 95%

“…For example, plasma vWF and thrombomodulin are used as indicators of endothelial dysfunction and/or damage [9,10]. In healthy people, the concentration of soluble thrombomodulin, which is determined by thrombomodulin gene polymorphisms, reflects the quantity of thrombomodulin expressed on the endothelial surface and increased expression of thrombomodulin may raise the concentrations of soluble thrombomodulin in the circulation [11].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension

Bulur

Özhan

Erden

et al. 2011

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The efficacy of olmesartan on fibrinolytic capacity has not been studied yet. Therefore, the aim of the present study was to investigate the efficacy of olmesartan on hemostatic/fibrinolytic status by measuring plasma level of plasminogen activator inhibitor-1 (PAI-1) and soluble thrombomodulin levels in patients with hypertension. Forty-two consecutive, newly diagnosed (25 women and 17 men with a mean age of 48 ± 8 years) patients with untreated essential hypertension were included in the study. Olmesartan medoxomil (20 mg/day) was started and the patients were followed up for 6 months. Baseline biochemical variables, thrombomodulin, and PAI-1 levels were compared with the levels of these variables measured at the end of the 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (from 159.5 ± 10.9 to 134.6 ± 12.7 mmHg and from 98.0 ± 6.3 to 83.9 ± 7.0 mmHg, respectively). Mean plasma PAI-1 and thrombomodulin levels were also significantly decreased (59.73 ± 41.91 vs. 48.60 ± 33.65 ng/ml, P = 0.001 and 8.09 ± 2.29 vs. 6.92 ± 1.42 μg/l, P < 0.001, respectively). Olmesartan medoxomil decreased plasma PAI-1 and thrombomodulin levels after 6 months of therapy, indicating a favorable effect on fibrinolytic capacity in patients with essential hypertension.

show abstract

Thrombomodulin as a marker of endothelium damage in some clinical conditions

Cited by 30 publications

References 16 publications

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Circulating Thrombomodulin Levels Are Related to Latent Progression of Atherosclerosis in Hypertensive Patients.

Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension

Contact Info

Product

Resources

About